Cisplatin Shortage Eases; Air Pollution Linked to Breast Cancer; Pap Test Confusion
(MedPage Today) -- The nation's supply of the widely used cancer drug cisplatin has almost returned to pre-shortage levels. (Becker's Hospital Review) The FDA announced a new and updated indication for temozolomide (Temodar) in anaplastic astrocytoma... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 15, 2023 Category: Hematology Source Type: news

FDA Updates Indications for Temozolomide FDA Updates Indications for Temozolomide
This is the second drug to receive a labeling update under the agency ' s Project Renewal program, which aims to keep labels of older cancer drugs up to date with current practice.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves New and Updated Indications for Temozolomide Under Project Renewal
On September 14, 2023, the Food and Drug Administration (FDA) approved updated labeling for temozolomide (Temodar, Merck) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for older... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2023 Category: Drugs & Pharmacology Source Type: news

FDA approves new and updated indications for temozolomide under Project Renewal
On September 14, 2023, the Food and Drug Administration (FDA) approved updated labeling for temozolomide (Temodar, Merck) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meani (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Possible Salvage Option for Refractory/Recurrent CNS Lymphoma Possible Salvage Option for Refractory/Recurrent CNS Lymphoma
This study shows cytarabine plus temozolomide may be an option. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Biomarkers found that could be drug targets against a deadly form of brain cancer
Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing hope for a cancer that is highly lethal. Currently, the drug most often used to treat glioblastoma, temozolomide, is uniquely able to cross the blood/brain barrier to attack the tumor but resistance develops rapidly, and many patients do not survive for more than a year after diagnosis. (Source: World Pharma News)
Source: World Pharma News - June 22, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Long-Term Temozolomide in Patients With Glioblastoma Long-Term Temozolomide in Patients With Glioblastoma
Temozolomide maintenance therapy looks promising in glioblastoma, but with caveats.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2022 Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Source Type: news

Trial to test if cannabis-based mouth spray can treat brain tumours
First such study in the world aims to find out if Sativex combined with chemotherapy can help treat glioblastomaCancer charities and the NHS are preparing to investigate whether a cannabis-based mouth spray can treat brain tumours and help patients to live longer.Doctors will give patients across the UK with a recurrent brain tumour called a glioblastoma the drug, which is known as Sativex, alongside a chemotherapy medication – temozolomide – in a clinical trial in an attempt to kill off cancerous cells.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2021 Category: Science Authors: Denis Campbell Health policy editor Tags: Cancer Cancer research UK news Medical research Health Science Source Type: news

CNIO scientists discovers a combination therapy for aggressive brain tumors
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * The researchers conducted an in-depth study of resistance to temozolomide, the first-line treatment for glioblastoma, to which many patients cease to respond over time* The combination of temozolomide and dianhydrogalactitol acts synergistically, overcomes this resistance and increases survival in mice with brain tumours* Treatments for glioblastoma have not improved in the last 20 years. The authors argue for the need to translate these results into clinical trials to study whether this combination therapy is also effective in patients with this disease (Source:...
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

Morning (vs Evening) Dosing and Better Survival in Glioblastoma Morning (vs Evening) Dosing and Better Survival in Glioblastoma
Taking temozolomide in the morning, rather than the evening, was associated with improved survival in some patients with newly diagnosed glioblastoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Temodar (temozolomide)
Title: Temodar (temozolomide)Category: MedicationsCreated: 4/6/2021 12:00:00 AMLast Editorial Review: 4/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 6, 2021 Category: Cancer & Oncology Source Type: news

Temozolomide for treatment of glioblastoma multiforme not cost effective in India
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2021 Category: Drugs & Pharmacology Source Type: news

Photon IMRT treatment group displays no significant survival difference between arms
(NRG Oncology) A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 26, 2020 Category: International Medicine & Public Health Source Type: news

Chemoradiation Boosts Glioblastoma Survival in Real-World Setting Chemoradiation Boosts Glioblastoma Survival in Real-World Setting
Adding systemic chemotherapy with temozolomide to radiotherapy offers a significant survival benefit over radiotherapy alone, study findings indicate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 13, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The structural basis of Focal Adhesion Kinase activation on lipid membranes unravelled
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Patients with glioma - a very common type of tumour originating in the brain - see improvement in survival rates with combined treatment of radiotherapy plus temozolomide* Researchers found a novel mechanism on how tumours evade chemotherapy through genomic rearrangements of the MGMT DNA repair gene* This finding is potentially relevant for updating the methods used to monitor temozolomide efficacy. Genomic rearrangement could be a marker to be detected in blood samples and help make therapeutic decisions (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news